Abstract
Sulfamated 2-ethylestra compounds have demonstrated strong anticancer activity, high bioavailability and an ability to bypass liver metabolism by reversibly binding carbonic anhydrase (CA) II in erythrocytes. Another CA isoform, CA IX, is overexpressed in many cancers. The CA domain of CA IX is oriented extracellularly, which may permit targeting inhibitors to tumors. Presented here is the characterization of three 2-ethylestra compounds bound to both CA II and a CA IX mimic protein. Inhibition by 18O exchange showed that compound 16 demonstrated an approximately 12-fold higher affinity for CA II over CA IX mimic. Structurally, compounds 15 and 16 showed alternate binding modes between CA II and CA IX mimic, apparently due to a water-mediated hydrogen bond to the isozyme-specific residue 67. Though the specificity was demonstrated for CA II over CA IX, this study reveals insights that may be key to developing isozyme specific CA inhibitors for novel anticancer therapies.
Keywords: Carbonic anhydrase, Isozyme specific, Structure based drug design, 2-Ethylestra compounds, Anti-cancer therapy, Steroid sulfatase inhibitors, Sulfamated 2-ethylestra compounds, erythrocytes, liver metabolism, estrogen, colchicine binding site, apoptosis, anti-angiogenic, PISA server, CA isoforms, cancer
Letters in Drug Design & Discovery
Title: Characterization of Carbonic Anhydrase Isozyme Specific Inhibition by Sulfamated 2-Ethylestra Compounds
Volume: 8 Issue: 8
Author(s): Katherine H. Sippel, Andre Stander, Chingkuang Tu, Balasubramanian Venkatakrishnan, Arthur H. Robbins, Mavis Agbandje-McKenna, Fourie Joubert, Annie M. Joubert and Robert McKenna
Affiliation:
Keywords: Carbonic anhydrase, Isozyme specific, Structure based drug design, 2-Ethylestra compounds, Anti-cancer therapy, Steroid sulfatase inhibitors, Sulfamated 2-ethylestra compounds, erythrocytes, liver metabolism, estrogen, colchicine binding site, apoptosis, anti-angiogenic, PISA server, CA isoforms, cancer
Abstract: Sulfamated 2-ethylestra compounds have demonstrated strong anticancer activity, high bioavailability and an ability to bypass liver metabolism by reversibly binding carbonic anhydrase (CA) II in erythrocytes. Another CA isoform, CA IX, is overexpressed in many cancers. The CA domain of CA IX is oriented extracellularly, which may permit targeting inhibitors to tumors. Presented here is the characterization of three 2-ethylestra compounds bound to both CA II and a CA IX mimic protein. Inhibition by 18O exchange showed that compound 16 demonstrated an approximately 12-fold higher affinity for CA II over CA IX mimic. Structurally, compounds 15 and 16 showed alternate binding modes between CA II and CA IX mimic, apparently due to a water-mediated hydrogen bond to the isozyme-specific residue 67. Though the specificity was demonstrated for CA II over CA IX, this study reveals insights that may be key to developing isozyme specific CA inhibitors for novel anticancer therapies.
Export Options
About this article
Cite this article as:
H. Sippel Katherine, Stander Andre, Tu Chingkuang, Venkatakrishnan Balasubramanian, H. Robbins Arthur, Agbandje-McKenna Mavis, Joubert Fourie, M. Joubert Annie and McKenna Robert, Characterization of Carbonic Anhydrase Isozyme Specific Inhibition by Sulfamated 2-Ethylestra Compounds, Letters in Drug Design & Discovery 2011; 8 (8) . https://dx.doi.org/10.2174/157018011796576105
DOI https://dx.doi.org/10.2174/157018011796576105 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Apoptosis-related BCL2-family Members: Key Players in Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Highlights in Peptide Nanoparticle Carriers Intended to Oral Diseases
Current Topics in Medicinal Chemistry Drug Targeting of Estrogen Receptor Signaling in the Cardiovascular System: Preclinical and Clinical Studies
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Natural Bioactive Compounds as Emerging Therapeutic Molecules Against Breast Cancer: Emphasis on the Role of Phytoestrogens
Current Drug Targets The Impact of In Vitro Fertilization on the Health of the Mother and the Offspring
Current Women`s Health Reviews Patent Selections
Recent Patents on Biomarkers Targeting Key Transporters in Tumor Glycolysis as a Novel Anticancer Strategy
Current Topics in Medicinal Chemistry Noradrenergic Regulation of Glial Activation: Molecular Mechanisms and Therapeutic Implications
Current Neuropharmacology Therapeutic Potential, Synthesis, Patent Evaluation and SAR Studies of Thieno[3,2-d]pyrimidine Derivatives: Recent Updates
Current Drug Targets Purines and Pyrimidines: Metabolism, Function and Potential as Therapeutic Options in Neurodegenerative Diseases
Current Protein & Peptide Science Improved Immunotoxins with Novel Functional Elements
Current Pharmaceutical Design Design of Zein Conjugation and Surface Modification for Targeting Drug Delivery
Current Drug Targets Strategies to Convert PACAP from a Hypophysiotropic Neurohormone Into a Neuroprotective Drug
Current Pharmaceutical Design Transcriptional Analysis of JAK/STAT Signaling in Glioblastoma Multiforme
Current Pharmacogenomics and Personalized Medicine Biologics: An Update and Challenge of Their Pharmacokinetics
Current Drug Metabolism Lapatinib as a Chemotherapeutic Drug
Recent Patents on Anti-Cancer Drug Discovery Patent Selections:
Recent Patents on Drug Delivery & Formulation Deubiquitinating Enzymes as Therapeutic Targets in Cancer
Current Pharmaceutical Design Sympathetic Signaling in Angiogenesis: Implications for Cancer Progression
Current Cancer Therapy Reviews Use of Gadoxetic Acid-enhanced MRI to Predict the Development of Postoperative Pancreatic Fistulas by Estimating the Degree of Pancreatic Fibrosis
Current Medical Imaging